Internal locus of control significantly moderated the relationship between medication barriers and anti-hypertensive medication adherence (beta = -.74, p < .01), being most beneficial when barriers are low.
Cross-Sectional (n=588)
Does locus of control moderate the relationship between medication barriers and anti-hypertensive medication adherence in hypertensive veterans?
Higher internal locus of control improves anti-hypertensive medication adherence when perceived barriers are low, but its benefit diminishes when perceived barriers are high.
Effect estimate: beta = -.74
p-value: p=< .01
Locus of control as a moderator of the relationship between medication barriers (e.g., side-effects, forgetting to take medication, and keeping track of pills) and anti-hypertensive medication adherence was examined. Baseline data were obtained from 588 hypertensive veterans. In general, fewer medication barriers, higher internal locus of control and lower external locus of control was associated with better hypertensive medication adherence. Furthermore, internal locus of control served as a moderator (beta = -.74, p < .01) for the relationship between medication barriers and medication adherence; effect size was large. Decomposition of the interaction revealed that the relationship between medication barriers and medication adherence was strongest when internal control was high (b = -.24, p < .01). Higher internal locus of control was beneficial when barriers to medication adherence are low, but at high perceived barriers, locus of control plays less of a role in medication adherence. Future efforts to improve medication adherence should consider the patient's perceived level of medication barriers in conjunction with their locus of control.
Hong et al. (Wed,) conducted a cross-sectional in Hypertension (n=588). Locus of control and medication barriers was evaluated on Anti-hypertensive medication adherence (beta = -.74, p=< .01). Internal locus of control significantly moderated the relationship between medication barriers and anti-hypertensive medication adherence (beta = -.74, p < .01), being most beneficial when barriers are low.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: